Results 71 to 80 of about 29,662,057 (278)
Sodium-glucose co-transporter type 2 inhibitors belong to modern class of oral hypoglycemic drugs, exerting its effect through the reduction of renal glucose reabsorption.
D. A. Lebedev +4 more
doaj
"Histological and Immunohistochemical Study of the Protective Effect of Sodium Glucose Co-transporter 2 (SGLT2) Inhibitors on Streptozotocin Induced Pancreatic Damage In Adult Male Albino Rats" [PDF]
Background: SGLT2 inhibitor is a type of medication prescribed for treatment of type 2 diabetes. By prevention the reabsorption of glucose in the kidneys, these drugs facilitate glucose removal through urine.Aim: Investigate protective effect SGLT2 ...
Abdel Hamid AboBakr +3 more
doaj +1 more source
SLC2A9 is a high-capacity urate transporter in humans [PDF]
Background Serum uric acid levels in humans are influenced by diet, cellular breakdown, and renal elimination, and correlate with blood pressure, metabolic syndrome, diabetes, gout, and cardiovascular disease. Recent genome-wide association scans have
Doblado M +240 more
core +1 more source
Preparation of RVG‐modified erythrocyte membrane‐coated HMPB nanocarriers loaded with L‐arginine and NBP (RM@HPAN) and its neuroprotective mechanism. After intravenous injection, RM@HPAN achieves prolonged circulation, RVG‐29‐mediated BBB penetration, and ischemic accumulation.
Shaofa Li +9 more
wiley +1 more source
Background: The effects of sodium–glucose co-transporter type 2 inhibitors on home blood pressure were examined in type 2 diabetes with nephropathy.
Osamu Tomonaga +4 more
core +1 more source
Renal Effects of Sodium-Glucose Co-Transporter Inhibitors [PDF]
Sodium-glucose co-transporter 2 (SGLT2) inhibitors immediately reduce the glomerular filtration rate (GFR) in patients with type 2 diabetes mellitus. When given chronically, they confer benefit by markedly slowing the rate at which chronic kidney disease
Thomson, Scott C, Vallon, Volker
core +1 more source
This study demonstrates that Tf‐PDA NPs combine a receptor‐mediated targeting with mild photothermal activation to enhance nanoparticle accumulation in the brain. NIR‐activated Tf‐PDA NPs increase BBB permeability to NPs in vitro and in vivo without inducing cytotoxicity or adverse immune responses.
Rafaela Ferrão +5 more
wiley +1 more source
REVIEW ONPHARMACOKINETICS OF EMPAGLIFLOZIN, AN INHIBITOR OF THE SODIUM GLUCOSE CO-TRANSPORTER-2 (SGLT-2) [PDF]
Empagliflozin is an inhibitor of the sodium glucose co-transporter-2 (SGLT-2), which is found almost exclusively in the proximal tubules of nephrotic components in the kidneys.
Nermeen Ashoush
core +3 more sources
Supplemental material, sj-pdf-2-vmj-10.1177_1358863X221101653 for Effect of sodium-glucose co-transporter-2 inhibitors on arterial stiffness: A systematic review and meta-analysis of randomized controlled trials by Dimitrios Patoulias, Christodoulos ...
Vassilios Vassilikos (4330294) +6 more
core +1 more source
Inspired by conventional cell therapy and emerging bioengineering approaches, the tissue‐engineered nigrostriatal pathway (TE‐NSP) has an anatomically‐inspired design comprising a population of human dopaminergic neurons with unidirectional, long‐projecting axon tracts.
Wisberty J. Gordián‐Vélez +8 more
wiley +1 more source

